20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Harmony Biosciences Holdings (HRMY) operates in the BIOTECHNOLOGY industry and is headquartered in Plymouth Meeting, United States with about 293 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, HRMY reported $868M in revenue and $159M in net income.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Interactive charts & full statements → Open the HRMY valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $960M | $868M | $715M | $582M | $438M | $305M | $160M | $6M | $0M |
| Gross Profit | $724M | $670M | $558M | $461M | $354M | $250M | $132M | $4M | $0M |
| Gross Margin % | 75.4% | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% | — |
| Operating Income (EBIT) | $231M | $208M | $191M | $192M | $120M | $88M | $17M | ($146M) | ($41M) |
| Operating Margin % | 24.0% | 24.0% | 26.7% | 33.0% | 27.5% | 28.7% | 10.6% | -2433.8% | — |
| Net Income | $181M | $159M | $145M | $129M | $181M | $35M | ($37M) | ($152M) | ($40M) |
| Net Margin % | 18.9% | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2535.1% | — |
| EBITDA | $276M | $255M | $233M | $222M | $147M | $80M | $2M | ($143M) | ($41M) |
| Earnings Per Share (EPS) | $3.09 | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-0.64 | $-2.39 | $-0.81 |
| Shares Outstanding (M) | 59M | 59M | 58M | 60M | 61M | 59M | 58M | 64M | 49M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $261M | $215M | $244M | $239M | $200M | $185M | $201M | $186M |
| Gross Profit | $198M | $171M | $175M | $180M | $162M | $153M | $147M | $143M |
| Gross Margin % | 75.8% | 79.3% | 71.9% | 75.1% | 81.0% | 82.7% | 73.0% | 77.0% |
| Operating Income (EBIT) | $89M | $37M | $39M | $65M | $48M | $56M | $56M | $62M |
| Operating Margin % | 34.2% | 17.3% | 15.8% | 27.4% | 24.0% | 30.4% | 27.7% | 33.2% |
| Net Income | $75M | $32M | $22M | $51M | $40M | $46M | $49M | $46M |
| Net Margin % | 28.9% | 15.1% | 9.2% | 21.2% | 19.8% | 24.7% | 24.6% | 24.8% |
| EBITDA | $102M | $49M | $52M | $73M | $59M | $67M | $66M | $72M |
| Earnings Per Share (EPS) | $1.28 | $0.55 | $0.38 | $0.87 | $0.68 | $0.78 | $0.85 | $0.79 |
| Shares Outstanding (M) | 59M | 59M | 59M | 59M | 58M | 59M | 58M | 58M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $355M | $348M | $220M | $219M | $144M | $99M | ($3M) | ($75M) | ($39M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M | $2M | $0M | $1M |
| Free Cash Flow (FCF) | $355M | $348M | $219M | $219M | $144M | $98M | ($5M) | ($76M) | ($40M) |
| FCF Margin % | 37.0% | 40.1% | 30.6% | 37.6% | 33.0% | 32.2% | -3.1% | -1260.8% | — |
| Dividends Paid | — | — | — | $5M | — | — | $200M | $144M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $92M | $28M | $126M | $109M | $79M | $34M | $76M | $71M |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | $92M | $28M | $126M | $109M | $79M | $34M | $75M | $70M |
| FCF Margin % | 35.4% | 12.9% | 51.7% | 45.4% | 39.6% | 18.3% | 37.3% | 37.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B | $1.3B | $999M | $811M | $674M | $433M | $427M | $107M | $89M |
| Cash & Cash Equivalents | $550M | $753M | $453M | $312M | $244M | $234M | $229M | $24M | $84M |
| Total Liabilities | $374M | $401M | $340M | $344M | $271M | $247M | $330M | $118M | $8M |
| Total Debt (Short + Long-Term) | $154M | $231M | $181M | $194M | $192M | $193M | $194M | $98M | $0M |
| Total Shareholders' Equity | $999M | $870M | $659M | $467M | $403M | $187M | $97M | ($12M) | $82M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HRMY viewer.
About TickerBase · Data methodology & sources · Privacy · Terms